• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Viking Therapeutics, Inc. (VKTX) Stock Price, News & Analysis

Viking Therapeutics, Inc. (VKTX) Stock Price, News & Analysis

Currency in USD Disclaimer

$52.59

$0.96

(1.86%)

Day's range
$51.95
Day's range
$53.52
50-day range
$47.65
Day's range
$81.73
  • Country: US
  • ISIN: US92686J1060
52 wk range
$11.55
Day's range
$99.41


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 133.01
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (VKTX)
  • Company Viking Therapeutics, Inc.
  • Price $52.59
  • Changes Percentage (1.86%)
  • Change $0.96
  • Day Low $51.95
  • Day High $53.52
  • Year High $99.41

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/05/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $110.00
  • High Stock Price Target $138.00
  • Low Stock Price Target $15.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.92
  • Trailing P/E Ratio -60.86
  • Forward P/E Ratio -60.86
  • P/E Growth -60.86
  • Net Income $-85,895,000

Income Statement

Quarterly

Annual

Latest News of VKTX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Viking Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of VKTX in the last quarter?

    In the last quarter Viking Therapeutics, Inc. earnings were on Wednesday, October, 23rd. The Viking Therapeutics, Inc. maker reported -$0.22 EPS for the quarter, beating analysts' consensus estimates of -$0.24 by $0.02.

  • What is the Viking Therapeutics, Inc. stock price today?

    Today's price of Viking Therapeutics, Inc. is $52.59 — it has increased by +1.86% in the past 24 hours. Watch Viking Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Viking Therapeutics, Inc. release reports?

    Yes, you can track Viking Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Viking Therapeutics, Inc. stock forecast?

    Watch the Viking Therapeutics, Inc. chart and read a more detailed Viking Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Viking Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Viking Therapeutics, Inc. stock ticker.

  • How to buy Viking Therapeutics, Inc. stocks?

    Like other stocks, VKTX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Viking Therapeutics, Inc.'s EBITDA?

    Viking Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Viking Therapeutics, Inc.’s financial statements.

  • What is the Viking Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Viking Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Viking Therapeutics, Inc.'s financials relevant news, and technical analysis. Viking Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Viking Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Viking Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.